Tech vendors should focus on implementation over experimentation

The healthcare industry can seem overloaded with new technological experiments, but companies focusing on implementation are ahead of the game, according to Forbes' David Shaywitz.

Whether the technology in question is artificial intelligence, wearables or telehealth, vendors focusing easy implementation are taking the extra step toward improved care. In the current medical landscape, technologies are being introduced without the implementation capabilities that allow healthcare systems to utilize them.

“While some consultants suggest we are further along than even their extravagantly optimistic predictions of 2013 had imagined, my own conversations with a range of stakeholders suggests progress has been painfully slow, and the practice of both medicine and drug development generally have not felt the impact of these emerging technologies, to put it very politely,” wrote Shaywitz.

Read the full story below:

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.